Diagnostic Criteria for Hematological Malignancies

Introduction to Blast Percentage

The presence of blasts on a peripheral blood smear is a critical finding that demands immediate diagnostic workup to distinguish between acute leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, or benign reactive conditions, with the blast percentage and clinical context determining both diagnosis and prognosis 1, 2.

Peripheral blood blasts ≥20% indicate acute leukemia, requiring immediate comprehensive evaluation and treatment initiation, as recommended by the European Hematology Association 1, 2.
Peripheral blood blasts of 2-4% with other myelodysplastic syndromes (MDS) features indicate RAEB-1 (Refractory Anemia with Excess Blasts-1), according to the International Working Group for the Prognosis of MDS 2, 3.
Peripheral blood blasts <5% with bone marrow blasts 5-19% classify as MDS rather than acute leukemia, as stated by the National Comprehensive Cancer Network 1, 2.

Peripheral blood blasts <5% with persistent monocytosis >1×10⁹/L and bone marrow blasts <20% define CMML, as defined by the World Health Organization 1, 5.

Higher peripheral blast percentages correlate with shorter survival and increased risk of leukemic transformation across myeloid neoplasms, as reported by the American Society of Clinical Oncology 2, 8.
The blast percentage is critical for International Prognostic Scoring System (IPSS) stratification in MDS, as recommended by the European LeukemiaNet 8.

Perform 500-cell differential count on peripheral blood smear to ensure reliable blast percentage determination, as suggested by the College of American Pathologists 9, 6, 3.
Bone marrow aspiration and biopsy with cytogenetics are mandatory even when peripheral blood shows diagnostic blast percentages, as required by the National Comprehensive Cancer Network 10, 2, 8.

Blasts are defined by high nuclear/cytoplasmic ratio, visible nucleoli, fine nuclear chromatin, variable cytoplasmic basophilia, with or without granules/Auer rods, as described by the World Health Organization 2.
Morphologic blast percentage takes precedence over flow cytometry for prognostic stratification, as stated by the International Society for Laboratory Hematology 10, 8.

CD34 immunohistochemistry is particularly valuable in hypocellular or fibrotic bone marrow specimens where morphologic assessment is inadequate, as recommended by the European Hematology Association 6, 7, 3.
Bone marrow cytogenetics (minimum 20 metaphases) are essential as chromosomal abnormalities occur in 50-60% of MDS cases and provide presumptive evidence of clonality, as reported by the American Society of Clinical Oncology 2.

Blast percentage <1% suggests aplastic anemia rather than MDS, though presence of easily identifiable megakaryocytes in architecturally disorganized marrow and reticulin fibrosis favor MDS, as described by the European Group for Blood and Marrow Transplantation 6, 7, 3.
Exclude reactive causes: infections, inflammatory conditions, solid tumors, copper deficiency (which can mimic MDS with dysplastic features), as recommended by the National Comprehensive Cancer Network 10, 5.

Any patient with circulating blasts requires same-day hematology consultation and bone marrow examination to establish definitive diagnosis, as required by the American Society of Hematology 1, 2, 8.